EACS2023: 275 Clinical and pharmacological outcomes of real-world use of Long-Acting Cabotegravir and Rilpivirine in France: efficacy and tolerance during the first 72 weeks C.K. Psomas , P. Halfon , M. Salnikova , H. Khiri , F. Tichadelle , J. Allemand , N. Néant , C. Solas , P. Philibert European Hospital Marseille, Department of Infectious Diseases and Internal Medicine, Marseille, France, Alphabio-Biogroup Laboratory, Marseille, France, APHM, Hôpital La Timone, Laboratoire de Pharmacocinétique et Toxicologie, Unité des Virus Émergents (UVE: Aix-Marseille Univ-IRD 190-Inserm 1207), Marseille, France General data Abstract category: Antiretroviral therapy – observational studies Abstract body Purpose: The first long-acting (LA) antiretroviral therapy (ART) regimen, represented by cabotegravir+rilpivirine (CAB+RPV) injection was approved by French authorities in January 2022 for virologically suppressed treatment-experienced patients (VL<50 copies/mL). Here we present data of clinical effectiveness and tolerance of CAB+RPV LA in people living with HIV (PWH) during the first 18 months of utilisation in the European Hospital of Marseille, France. Method: From 1 of January 2022 until the 31 of May 2023, virologically suppressed ART experienced PWH were treated using CAB+RPV and followed using clinical and electronical health record data. HIV-1 viral load (VL), CD4 T-cell count, and pharmacological monitoring were assessed from first injection till end of follow up or discontinuation. Results: Of 142 participants prescribed CAB+RPV, 98.5% had undetectable VL during the switch. 21.8% were women, the median age was 51 (IQR:22-79) years, the mean BMI was 24,41 (13.66; 38.5) and 11 (7.7%) participants had a BMI over 30. Last ART regimen is represented in the figure. At study end, 14 participants (9,8%) discontinued CAB+RPV: 11 had local Adverse Events (AEs), 1 had psychiatric AE, and 1 had a virologic failure because of delayed injection. No BMI variation was observed during the study. 82 out of 142 participants had therapeutic drug monitoring; 56 (68%) of these had at least one drug concentration below alert threshold (CAB=1,120 ng/ml; RPV=32 ng/ml) over the follow up period, of whom 18 (32%) had recurrent suboptimal concentrations concerning mostly CAB. Conclusions: In this real-world cohort of PWH who received CAB+RPV LA injections in Marseille, observations suggest that this regimen is effective and well tolerated in virologically suppressed individuals, with adverse events consistent with clinical studies. Participants should be closely monitored, in order to maintain on-time injections. General conditions 1. I confirm that I previewed this abstract and that all information is correct. I accept that the content of this abstract cannot be modified or corrected after the submission deadline and I am aware that it will be published exactly as submitted.: Yes 2. I confirm that the submission of the abstract constitutes my consent to publication (e.g. conference website, programmes, other promotions, etc.). : Yes 3. I herewith confirm that the contact details saved in this system are those of the corresponding author, who will be notified about the status of the abstract. The corresponding author is responsible for informing the other authors about the status of the abstract.: Yes 4. I agree that all data provided may be used (saved, stored, processed, transmitted and deleted) in compliance with the privacy policy to provide the services described.: Yes 1 1 1 2 1 1 3 3 1 1 2 3 st st 94 19TH EUROPEAN AIDS CONFERENCE | WARSAW 2023
RkJQdWJsaXNoZXIy Mzc2ODc=